Nxera Pharma Co., Ltd.
SOLTF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $8 | $7 | $7 |
| % Growth | -99.5% | 27.2% | -3% | – |
| Cost of Goods Sold | $0 | $2 | $2 | $2 |
| Gross Profit | $0 | $7 | $5 | $5 |
| % Margin | 60.4% | 78% | 75.7% | 69% |
| R&D Expenses | $0 | $4 | $4 | $3 |
| G&A Expenses | $0 | $0 | $0 | -$1 |
| SG&A Expenses | $0 | $4 | $4 | $1 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $2 |
| Other Operating Expenses | $0 | $0 | -$0 | $4 |
| Operating Expenses | $0 | $8 | $7 | $8 |
| Operating Income | -$0 | -$1 | -$2 | -$4 |
| % Margin | -51.7% | -14.5% | -33% | -55% |
| Other Income/Exp. Net | $0 | -$0 | $0 | $1 |
| Pre-Tax Income | -$0 | -$2 | -$2 | -$2 |
| Tax Expense | -$0 | $1 | $1 | $1 |
| Net Income | -$0 | -$2 | -$1 | -$1 |
| % Margin | -24.8% | -28.1% | -11.4% | -19.5% |
| EPS | -0.12 | -26.35 | -8.45 | -14.85 |
| % Growth | 99.5% | -211.8% | 43.1% | – |
| EPS Diluted | -0.12 | -26.35 | -8.45 | -14.86 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $1 | $0 | $0 |
| Depreciation & Amortization | $0 | $1 | $1 | $1 |
| EBITDA | -$0 | $1 | -$1 | -$3 |
| % Margin | -26.7% | 6.3% | -16.7% | -40.5% |